Shenzhen Kangtai Biological Products Co., Ltd. (stock code: 300601) was established in 1992. It focuses on the research and development, production, and sales of human vaccines. It has now developed into a leading innovative biopharmaceutical enterprise in China with strong research capabilities, a rich product portfolio, industry-leading scale, and significant international progress.

The company has five major R&D and industrial bases in Shenzhen and Beijing and possesses a diverse R&D platform that includes live attenuated viral vaccines, inactivated viral vaccines, recombinant protein vaccines, bacterial polysaccharide vaccines, bacterial polysaccharide conjugate vaccines, combination vaccines, viral vector vaccines, mRNA vaccines, and new adjuvant technologies. This provides a solid foundation for the transformation of cutting-edge vaccine technologies.

Kangtai has 11 products that have been approved for market launch or emergency use, including the world's first 60-microgram hepatitis B vaccine, the "dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine," and the first "four-dose" human diploid cell rabies vaccine approved in China. Its marketing and distribution network covers 31 provinces (autonomous regions, municipalities directly under the Central Government) in China.